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Summary Study objective: To assess whether asthmatic children may generate
sufficient peak inspiratory flow through the Novolizers, a novel multiple dose dry
powder inhaler with acoustic and optical feedback mechanisms for correct
inhalation.
Patients and methods: 137 children (median age 7 years, range 4–12) with mild to
moderate persistent asthma (FEV1 o90% predicted or pre-treated with low-dose
steroids) participated in this open, multi-centre study. After assessment of FEV1 and
peak inspiratory flow (without inhalator device, PIF), the children were instructed to
inhale with the Novolizers (PIF through inhaler, PIF-N). All assessments were done in
triplicate and the mean out of three attempts analysed.
Results: Mean PIF was 128 7 61 l/min and mean PIF-N was 69 7 18 l/min. This is
distinctly above the rate necessary to overcome the Novolizers’s trigger threshold.
PIF performance through the Novolizers was linear in the age interval of 4–8 years,
no further increase was observed beyond 8 years.
Conclusions: The medium to low intrinsic resistance of the Novolizers permits a
relatively high PIF through this device. Together with the feedback mechanisms, this
makes the Novolizers particularly valuable for inhalation therapy in asthmatic
children with drugs such as salbutamol, formoterol, or budesonide.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
For many years the inhalation of drugs has been a
proven measure in the treatment of bronchial
asthma 1 and chronic obstructive pulmonary dis-
ease.2 In that way and in contrast to systemic
treatment, the ratio of desired effects to
adverse reactions can be improved considerably
by inhalation.1,2
At present, pressurised metered dose inhalers
(pMDIs) are the most commonly used device for the
inhalation of drugs targeted to the lungs. Until
recently, pMDIs contained chlorofluorocarbon (CFC)
propellants. In search of alternatives, new propel-
lants for CFC-free pMDIs as well as dry powder
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inhalers (DPI) containing no propellants at all have
been developed.
Both from an ecological and medical point of
view, DPIs have certain advantages over the pMDIs.
The optimal use of pMDIs requires the coordination
of the actuation with appropriate timing of
inspiration. Several studies showed that only
approximately 25% of adult patients are able to
perform a correct inhalation manoeuvre.3,4 Coor-
dination of actuation and inhalation is, however,
not necessary for a dry powder inhaler. Even
children as young as 8 years are able to use a DPI
correctly.5 Moreover, when inhaling an active
substance by means of a DPI, there is no cold
sensation of propellants, nor are surface-active
substances inhaled. On the other hand, conven-
tional DPIs offer no possibility for operator control
of a correct inhalation. However, delivery of the
drug dose into the lung depends on a sufficient
inspiratory flow generated by the patient.6 There-
fore a device with a low to medium resistance
might be of importance, especially for children
and for an effective use during an acute asthma
attack.
The Novolizers is an example of an alternative
non-propellant inhalation device: a multiple dose
dry powder inhaler (MDPI). The patient inhales
micronised active substance and carrier from the
device, i.e. the powder is transported to the lungs
by a stream of inhaled air. The Novolizers contains
up to 200 doses in a replaceable cartridge and can
therefore be characterised as a refillable, multi-
dose, multi-use device. Recently a Novolizers
delivering 200 mg of budesonide per dose has been
registered in the EU for the treatment of adults and
children of 6 years and older. The device has a low
to medium airflow resistance (0.0260 kPa0.5min l–1),
which is illustrated in Fig. 1, relative to the flow
resistance of the Turbohalers and the Aerolizers.7
Clinical studies demonstrated the therapeutic
efficacy and safety of the Novolizers in adult
patients with asthma and COPD equivalent to the
Turbuhalers.8,9 Deposition of budesonide in the
lungs (assessed by gamma scintigraphy) achieved
via the Novolizers was at least as much as via the
Turbuhalers when both devices were used at
similar flow rates.10 In vitro and in vivo flow rate
dependency was found for the Novolizers as for
most other DPIs.7,11. The trigger threshold of the
Novolizer isbetween35and50 l/min.TheNovolizers
is easy to use, which makes it particularly useful for
the paediatric population. In addition, its visual
and acoustic feedback mechanisms are of particu-
lar value for the use in children, since for the first
time direct evidence is provided for parents and
other supervisors indicating that the inhalation
manoeuvre was carried out indeed in the right
manner (Fig. 2).
Currently, little data exist about the applicability
of the Novolizers in paediatric patients. Therefore
the objectives of this study were to assess whether
children aged 4–11 years with stable bronchial
asthma are able to generate sufficient peak
inspiratory flow through the Novolizers (PIF-N)
and to assess whether these children can effec-
tively operate this device after adequate instruc-
tion. In order to further characterise the study
population, FEV1 and peak inspiratory flow (PIF)
were assessed and correlated to each other, to the
PIF-N and to the children’s age.
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Figure 1 In vitro flow resistance of different DPIs modified according to Fyrnys et al.7
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Patients and methods
The trial was designed as an open label multi-
centre study. As the Novolizers was used with an
empty cartridge, no medication was administered
for the purpose of this trial.
Patients
Male or female children of 4–11 years could be
included, provided that they had a history and
current clinical evidence of bronchial asthma of any
origin, and they either had a baseline FEV1 o90%
predicted or were pre-treated with inhaled steroids
up to a maximum of 400 mg budesonide per day (or
equivalent daily dosages of other inhaled steroids).
There was no specific recommendation regarding
use or non-use of concomitant medication; how-
ever, restrictions of concomitant medication before
lung function testing were as follows: short-acting
b-agonists and anticholinergics for 6 h, long-acting
b-agonists, inhaled corticosteroids, leukotriene
antagonists, theophylline, cromoglycate, or nedo-
cromil for 12 h. Patients who had experienced an
exacerbation of asthma during the previous week
were excluded. When conducting the trial, Novo-
lizers products (such as the budesonide delivering
product) were not yet indicated for the use in
children below 12 years. In fact, none of the
participating children had prior experience with
this device, i.e. they may be characterised as
Novolizer-naives, as confirmed by the prior medi-
cation records.
Inhalation
After the assessment of FEV1 and PIF, the investi-
gators concisely instructed the children in the
correct use of the Novolizers. Each patient inhaled
three times12,20 through the Novolizers device in
order to assess the PIF-N. For these measurements
patients were instructed to inhale as fast and hard
as they could through the Novolizers. No test or
learning inhalations were allowed and no child had
prior experience with the Novolizers. The PIF-N
and simultaneously the ability to operate the
Novolizers was assessed with a device connected
in series with the lung function diagnostic equip-
ment. This construction allowed the assessment of
the actual peak inspiratory flow values achieved
through the PIF-N. Hence, an individually pre-
numbered device was put into a specially designed
airtight box which was linked in series with the
Jaeger MasterScopes pneumotachograph (Jaeger,
Hochdorf, Germany; pneumotachographic principle
of flow measurement, used to calculate the
volumes for spirometry). The Jaeger Master-
Scopes is a well-known and validated device,
certified according to ISO 9001, CE- as well as
FDA-registered, and fulfils criteria of the German
and European law on medicinal devices.13 Analogue
procedures for the assessment of inspiratory flow
were used by other authors.12,22,24
The experimental circumstances required a fixed
position of the device in the box and a fixed
position of the box. Furthermore, the box partially
covered the mouth piece of the Novolizers
diminishing the length of it. The airtight box that
covered the Novolizers was constructed in a
manner not influencing the flow assessments. Each
airtight box used in this trial was tested and the
system box–Novolizer–Masterscope was validated
(Sofotec, Frankfurt am Main, Germany) prior to
providing the centres with the equipment.
For the purpose of quality assurance, the investi-
gators judged, for each inhalation through the
Novolizers, whether the inhalation manoeuvre was
performed according to the instruction. This allowed
the exclusion of erroneous measurements. The
decision whether the trigger threshold had been
overcome was based on the occurrence of both, the
acoustic and visual indicator of the device.
Ethics
Study protocol and patient’s informed consent
were reviewed by an Independent Ethics Commit-
tee. Parents and patients’ informed and written
consents were obtained prior to enrolment.
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Figure 2 The multidose dry powder inhaler Novolizers.
Dose metering is performed by pressing down the dosage
button. When the function indicator colour changes from
the colour of the dosage button to green, the inhaler is
ready for use. The counter mechanism can be seen in the
upper control window.
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The trial was carried out in accordance with the
laws and guidelines current at that time: the
German law on Medical Devices, the principles of
the Declaration of Helsinki, and the Guideline for
Good Clinical Practice.
Statistics
All statistical evaluations and analyses were per-
formed using SASt 8.2. The analysis of the study
was performed in a descriptive and exploratory
manner. The three documented FEV1 measure-
ments were condensed to the individual maximum
value (best of three), PIF and PIF-N measurements
were analysed primarily as individual means;
individual maximum, minimum and 1st attempt
values are also presented. Appropriate analyses by
age group, analyses of correlation, and linear
regressions between variables were performed
additionally. The sample size considerations
were based on a former study with an Allergospas-
mins Novolizers (study code 3187, data on file )
and yielded a precision of estimations of about
20 l/min for PIF and about 3 l/min for PIF-N with
120 patients based on 95% 2-sided confidence
limits.
Results
The study was performed at 7 centres in Germany.
A total of 138 patients were screened, for 137 of
them PIF measurements were available, represent-
ing the ITT population. Ethnic origin of patients was
Caucasian for 97.8% and other for 3/137 (2.2%) of
patients. Most patients (92, 67.2%) already had
experience with spirometry procedures. A summary
of demography and baseline characteristics is
provided in Table 1.
PIF-N data from one child are not available due
to computer problems, thus, 136 children provided
PIF-N data. All except 5 patients were able to
overcome the trigger threshold, i.e. 131 of 136
(96.3%). All 5 children who were unable to over-
come the trigger threshold were in the age class
4–5 years ð5=32 ¼ 15:6%Þ: Most patients, namely
116 (85.3%) were successful in overcoming the
trigger threshold in all three attempts; 10 (7.4%)
patients were successful at two attempts, and 5
(3.7%) patients were successful at only 1 attempt.
In addition to the 116 children who inhaled
successfully at all 3 attempts, 6 children inhaled
only twice and both attempts were successful;
another 4 children had a successful first attempt,
but, failed at one of the following. Thus, 126
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Table 1 Demographics and baseline lung function data from all patients with available PIF.
Variable All patients 4–5 yr 6–7 yr 8–9 yr 10–11 yr
N¼ 137n N¼ 32 N¼ 37 N¼ 30 N¼ 35
Age (years)
Mean7SD 7.772.3 4.770.5 6.570.5 8.570.5 10.570.5
Range 4–12 4–5 6–7 8–9 10–11
Sex
% males 56.9 56.3 70.3 53.3 48.6
Height (cm)
Mean7SD 130714 11377 12576 13577 14778
Range 94–166 94–125 112–138 120–149 124–166
Weight (kg)
Mean7SD 30.0710.2 20.373.9 25.575.0 32.378.4 41.178.0
Range 15–58 15–32 19–45 21–49 23–58
BMI
Mean7SD 17.273.1 15.972.5 16.472.2 17.773.4 19.173.4
Range 11.8–28.3 12.8–23.8 11.8–24.3 12.9–24.0 13.3–28.3
FEV1 (l)
nn
Mean7SD 1.5470.53 0.9770.30 1.4570.27 1.6370.52 1.9270.56
Range 0.47–3.22 0.47–1.53 0.98–2.23 0.87–3.00 0.56–3.22
FEV1 (%) predicted.
nn
Mean7SD 92.0723.2 85.1725.4 103.7720.4 90.7721.0 85.0723.5
Range 27–150 42–132 52–150 56–133 27–125
nIncluding 3 patients older than 11.
nnNo data for centre 6.
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(92.6%) of the children had a successful first
attempt.
Successful inhalation manoeuvres were accom-
panied by mean PIF-N measurements of 72.0 l/min
(range: 37.8–130.2 l/min). A total of 373 attempts
was included in this calculation. The 26 inhalation
manoeuvres which failed overcoming the trigger
threshold were accompanied by mean PIF-N mea-
surements of 35:6712:4 l=min: For the 131 patients
who passed the trigger threshold at least once the
PIF-N (maximum of all attempts) was 77.4 l/min
(43.8–130.2 l/min). Table 2 summarises the de-
scriptive statistics of PIF and PIF-N for all patients
with at least one PIF measurement and by age
group. No coughing was provoked by the inhalation.
PIF increased on average with age, which was not
observed for PIF-N (Fig. 3). The group 10–11 years
had higher PIF than the group 8–9 years, whereas
no such pattern was observed for PIF-N.
Pearson correlation coefficients were calculated
and regression analyses investigating the correla-
tion between age, FEV1, and FEV1%-predicted on
the one hand and PIF and PIF-N on the other hand as
well as between PIF and PIF-N were performed
(Table 3). In the interpretation of PIF-N results it
has to be considered that no further increase was
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Table 2 Peak inspiratory flow [l/min] (mean, maximum, minimum, and 1st of three attempts) from all patients
with available PIF measurements.
Variable All patientsn 4–5 yr 6–7 yr 8–9 yr 10–11 yr
Mean of three attempts
PIF
Mean7SD 128761 78736 118735 140771 173760
N 137 32 37 30 35
PIF-N
Mean7SD 69718 55715 68714 79718 76716
N 136 32 37 29 35
PIF-N/PIF
Mean7SD 0.6470.31 0.8470.46 0.6270.17 0.6470.23 0.5070.21
N 136 32 37 29 35
Maximum of three attempts
PIF
Mean7SD 147766 91738 138738 164776 191765
N 137 32 37 30 35
PIF-N
Mean7SD 76719 60714 76716 86719 83718
N 136 32 37 29 35
PIF-N/PIF
Mean7SD 0.5970.26 0.7670.38 0.5870.15 0.5870.19 0.4970.20
N 136 32 37 29 35
Minimum of three attempts
PIF
Mean7SD 108760 64735 96737 115770 153760
N 137 32 37 30 35
PIF-N
Mean7SD 63717 49716 61713 72717 70715
N 136 32 37 29 35
1st attempt
PIF
Mean7SD 124763 80737 110738 137775 163764
N 136 31 37 30 35
PIF-N
Mean7SD 66718 54717 63714 74717 74716
N 136 32 37 29 35
nIncluding 3 patients older than 11.
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observed beyond the age of 8 years, and fitting a
linear relation model appeared inadequate. Never-
theless, it was done for completeness. FEV1%
predicted did not correlate well with PIF. As
expected, PIF and PIF-N showed the best, though
by far no close correlation (r2 ¼ 0:32; correlation
coefficient 0.57) (Table 3, Fig. 4).
Discussion
With DPIs, efficient release and deposition of
medication dependsFamong other factorsFon
an adequate PIF. Although it was shown that the
PIF as a sole variable is not sufficient to judge
the quality of an inhalation,14 drug deposition in
the respiratory tract is to a large extent deter-
mined by an adequate PIF. Also the fine particle
fraction, a major factor for peripheral drug
deposition in the lung, is substantially flow depen-
dent. In a study evaluating lung deposition of
radiolabelled budesonide inhaled through the No-
volizers or Turbuhalers at different flow rates, a
significant correlation between lung deposition and
PIF was found,11 while the ratio between peripheral
and central zone deposition as the oropharyngeal
deposition was not influenced by a change in PIF.
However, the Turbuhalers had a significantly higher
oropharyngeal deposition. Similar effects were
noticed in studies with other devices.15 As PIF
through a device is higher when the device’s airflow
resistance is lower,16 an inhalation device with a
low to medium airflow resistance such as the
Novolizers might improve the drug deposition in
the respiratory tract. An increase in inspiratory
flow has been shown to increase the proportion of
respirable particles, and instructing patients to
inhale ‘‘forcefully and deeply’’ rather than ‘‘dee-
ply’’ has proved to be more effective.17 Our
patients were instructed to inhale ‘‘as fast and
hard as they could’’. Therefore we conclude that
patients who had overcome the threshold inhaled
with sufficient acceleration.
In our study PIF and PIF-N were analysed in stable
asthmatic children (either FEV1 predicted o90% or
pre-treated with low-dose inhaled steroids). Two-
thirds of the children had experience with inhalers,
and most of them had experience with powder
inhalers. For all, it was the first time ever inhaling
through the Novolizers. Furthermore, after the
instruction to utilise the Novolizers, they were
given no opportunity to train the inhalation.
Bronsky et al.18 assessed inspiratory flow rates in
32 asthmatic children (mean age 9.6 years, range7–
11). The mean PIF (through spirometer alone) was
154 l/min. This compares well with the mean PIF
(mean out of three attempts) in this study, 148 l/
min, when the same age group is considered (7–11
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Figure 3 Scatter plot of age versus PIF-N (maximum of
three attempts). All patients with at least one available
PIF-N measurement (r2 ¼ 0:18). The upper and lower
specification limits for the trigger threshold are indicated
by the dashed lines. Note that the linear fit shown might
be inadequate for this data set.
Table 3 Pearson correlation coefficients between
PIF, PIF-N, and remaining variables.
Variables PIF (l/min) PIF-N (l/min)
Age (yr)n 0.56 0.44
FEV1 (l)
nn 0.66 0.54
FEV1 predicted (%)
nn 0.23 0.27
PIF (l/min)n 1.00 0.57
Peak inspiratory flow (mean of three attempts); Pearson’s
correlation coefficients; patients with available PIF and
PIF-N measurements
nN¼ 136.
nnN¼ 100.
Figure 4 Scatterplot of PIF versus PIF-N (maximum of
three, each). All patients with available PIF and PIF-N
measurement (r2 ¼ 0:32).
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years, n ¼ 85). Thus, our methodology is in line
with the published data, which can be regarded as
an external validation.
We found a correlation of PIF with age; however,
children above 8 years of age, always being clearly
above the device’s trigger threshold, showed only
little further increase in PIF-N with age. This confirms
previous findings, where PIFs through another powder
inhaler device named Diskuss or Accuhalers were
investigated and a non-linear relationship between
age and PIF–Diskus was found.19 The relationship
tended to be almost linear up to 8 years after which
the curve reached a plateau.
Compared to other inhalation devices, the
percentage difference between mean PIF and mean
PIF through the device (PIF-N) was with 46% (mean
out of three attempts) rather low, reflecting the
fact that the Novolizers has a low to medium air
flow resistance (0.0260 kPa0.5min l–1). Engel et al.20
performed PIF measurement through the Turbuha-
lers in 101 adult asthmatic patients with a mean
FEV1 predicted of 68%. That study showed a
stronger difference between PIF without and with
Turbuhalers (261 vs 59 l/min), i.e. a 75% reduction
of inspiratory flow. In fact the Turbuhalers has a
high air flow resistance (0.0367 kPa0.5min l–1).
A percentage of 96% of the children succeeded to
overcome the individual trigger threshold of the
Novolizers. Only 5 children, all younger than 6
years, were unable to overcome the trigger thresh-
old. The mean PIF-N rates achieved by children
aged 4–12 years were distinctly above the technical
trigger threshold. This trigger threshold was de-
signed at a PIF-N, which has demonstrated a
sufficient lung deposition for drugs delivered by
the Novolizers;7,11 it is in the flow range of
35–50 l/min. Another study showed that children
of 6 years and older are usually able to achieve a
PIF 440 l/min.5 Compared to studies with the
Turbuhalers, where a considerable proportion of
children even older than 6 years failed to achieve a
PIF 430 l/min through the Turbuhalers,21,22 all
children in our study, whose PIF-N was o35 l/min,
were younger than 6 years.
An important aspect of the Novolizers compared
to other inhalers is that it provides an indication for
an adequate inhalation flow. The visual feedback
(changing from green to red) and the acoustic
feedback (‘‘click’’) which follow adequate inhala-
tion manoeuvres offer the opportunity to protect
against unintentional underdosing. Thus, the No-
volizers is one of the first inhalation devices that
offers parents and caregivers the possibility to
control correct inspiratory flow manoeuvres of
their children, which makes the Novolizers espe-
cially useful for paediatric patients.
PIF depends upon multiple factors such as
inspiratory musculature or airway diameter. At
least from paediatric cystic fibrosis patients it is
known that PIF does not correlate with predicted
values of expiratory flow.23 In our study, the best,
though by far imperfect predictor for PIF, was FEV1.
Our data correspond with previously published
investigations on the Turbuhalers, where the
regression analysis of FEV1 and PIF-Turbuhaler led
to r2 ¼ 0:31 (P ¼ 0:001).1 No relevant correlation
between PIF-Turbuhaler and FEV1% of predicted
was found ðr2 ¼ 0:18Þ: The PIF-Turbuhaler could not
be accurately predicted by measurements of FEV1
or PEF. Even inhalation of salbutamol did not
influence the PIF values: the PIF-Turbuhalers
showed a slight insignificant increase from 55 to
59 l/min, although FEV1 increased significantly from
2.40 to 2.90 l 15min after inhalation. Meijer et al.
confirmed the results in 29 asthmatic patients
characterised by FEV1 predicted of 88% with an
average PIF of 68 l/min and individual mean PIF-
Turbuhalers values ranging from 55 to 95 l/min.24
In summary, data available suggest that common
measures of expiratory lung function are poor
predictors of inspiratory performance.
In general, the PIF-N data measured in our study
appear to realistically describe the inspiratory
performance of asthmatic children. The fact that
5 of the 32 children younger than 6 years failed to
correctly inhale should not lead to generally
exclude children of this age group from treatment
with the Novolizers device because the feedback
mechanism allows to distinguish between an
unsuccessful and a successful attempt. Our study
indicates that 27 of the 32 (84%) children younger
than 6 years and all 104 children above 6 years with
stable bronchial asthma are able to generate a
sufficient peak inspiratory flow through the Novo-
lizers to overcome the trigger threshold and to
operate effectively this device after adequate
instruction.
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